Modalis Therapeutics logo

4883 - Modalis Therapeutics Share Price

¥2633 -2.0  -0.1%

Last Trade - 7:00am

Market Cap £545.8m
Enterprise Value £525.5m
Revenue £4.79m
Position in Universe 913th / 3864
Bullish
Bearish
Unlock 4883 Revenue
Momentum
Relative Strength (%)
1m -19.0%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -35.3%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 65.3 644.5 +887%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2020, Modalis Therapeutics Corp revenues totaled Y337M. Net income applicable to common stockholders totaled to Y26.9M.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

4883 Revenue Unlock 4883 Revenue

Net Income

4883 Net Income Unlock 4883 Revenue

Normalised EPS

4883 Normalised EPS Unlock 4883 Revenue

PE Ratio Range

4883 PE Ratio Range Unlock 4883 Revenue

Dividend Yield Range

4883 Dividend Yield Range Unlock 4883 Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
4883 EPS Forecasts Unlock 4883 Revenue
Profile Summary

Modalis Therapeutics Corp is a Japan-based company engaged in the research and development of gene therapy drugs using the core platform CRISPR-GNDM technology. The Company develops gene therapy drugs that use CRISPR-GNDM technology, which is a unique platform technology, for genetic diseases caused by errors in the genetic code and epigenetics. The Company has two business models. Collaborative model pipeline opens CRISPR-GNDM technology to partners, and develops therapeutic drugs with partners' funds for the targets selected by the partners. In-house model pipeline selects targets using the Company's own CRISPR-GNDM technology and develops therapeutic agents. The Company's pipeline consists of a collaborative model pipeline of 5 items such as MDL-201 and an in-house model pipeline of 2 items such as MDL-101.

Directors
Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated January 14, 2016
Public Since August 3, 2020
No. of Shareholders: n/a
No. of Employees: 16
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange Tokyo Stock Exchange
Shares in Issue 27,880,000
Free Float (0.0%)
Eligible for
ISAs
SIPPs
4883 Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for 4883
Upcoming Events for 4883
Frequently Asked Questions for Modalis Therapeutics
What is the Modalis Therapeutics share price?

As of 7:00am, shares in Modalis Therapeutics are trading at ¥2633, giving the company a market capitalisation of £545.8m. This share price information is delayed by 15 minutes.

How has the Modalis Therapeutics share price performed this year?

Shares in Modalis Therapeutics are currently trading at ¥2633 and the price has moved by % over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Modalis Therapeutics price has moved by % over the past year.

What are the analyst and broker recommendations for Modalis Therapeutics?

There are no analysts currently covering Modalis Therapeutics.

When will Modalis Therapeutics next release its financial results?

Modalis Therapeutics is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Modalis Therapeutics dividend yield?

Modalis Therapeutics does not currently pay a dividend.

Does Modalis Therapeutics pay a dividend?

Modalis Therapeutics does not currently pay a dividend.

When does Modalis Therapeutics next pay dividends?

Modalis Therapeutics does not currently pay a dividend.

How do I buy Modalis Therapeutics shares?

To buy shares in Modalis Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Modalis Therapeutics?

Shares in Modalis Therapeutics are currently trading at ¥2633, giving the company a market capitalisation of £545.8m.

Where are Modalis Therapeutics shares listed? Where are Modalis Therapeutics shares listed?

Here are the trading details for Modalis Therapeutics:

Country of listing: Japan
Exchange: TYO
Ticker Symbol: 4883
What kind of share is Modalis Therapeutics?

Based on an overall assessment of its quality, value and momentum, Modalis Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Modalis Therapeutics share price forecast 2020?

We were not able to load any forecast data for Modalis Therapeutics.

How can I tell whether the Modalis Therapeutics share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Modalis Therapeutics. Over the past six months, the relative strength of its shares against the market has been %. At the current price of ¥2633, shares in Modalis Therapeutics are trading at -10.22% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Modalis Therapeutics PE Ratio?

The Modalis Therapeutics PE ratio based on its reported earnings over the past 12 months is 0.442k. The shares are currently trading at ¥2633.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Modalis Therapeutics?

Modalis Therapeutics's management team is headed by:

Haru Morita - PRE
Tetsuya Yamagata - SVP
Naoki Kobayashi - CFO
Osamu Nureki - IND
Joseph McCracken - IND
Miyuki Shimane - IND
Teruhisa Tajima - IND
Toshio Furuta - IND
Who are the major shareholders of Modalis Therapeutics?

Here are the top five shareholders of Modalis Therapeutics based on the size of their shareholding:

KK Life Science Innovation Management Corporation
Percentage owned: 17.33% (4.83m shares)
Nureki (Osamu) Individual Investor
Percentage owned: 15.6% (4.35m shares)
Fast Track Initiative, Inc. Venture Capital
Percentage owned: 4.62% (1.29m shares)
SBI Investment Co., Ltd. Venture Capital
Percentage owned: 4.56% (1.27m shares)
Rheos Capital Works Inc. Investment Advisor
Percentage owned: 4.15% (1.16m shares)
Similar to 4883
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.